Sorry, we should give it a month.
December should be a great month.
I can't see this management reversing the trend. From $2.17 to $1.655 and now is a miserly $1.80. This share has a weak following and lacks investment fundamentals.
Buy at your own risk. It will take an ARR upgrade or another good acquisition to fight the shorters that are flooding this stock.
- Forums
- ASX - By Stock
- VHT
- Ann: Volpara DENSE trial results published
Ann: Volpara DENSE trial results published, page-16
Featured News
Add VHT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online